Establishing a Repository of Blood & DNA Samples From People With Sickle

Status Terminated

Clinical Trial Summary

Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. The purpose of this study is to collect, test, and archive blood and DNA samples from children and adults with SCD to study the role that genes play in SCD. Blood and DNA samples will be stored for use in future SCD studies.

Clinical Trial Description

SCD is an inherited blood disorder that is caused by an abnormal type of hemoglobin. Symptoms include anemia, infections, organ damage, and intense episodes of pain, which are called "sickle cell crises." The Comprehensive Sickle Cell Centers (CSCC) is a network of 10 centers that conduct research to improve health care and treatment options for people with SCD. The Collaborative Data Project (C-Data) is a CSCC study that is establishing a comprehensive database of children and adults with SCD who are receiving medical care at participating CSCC research centers. This study will initiate the development of a centralized laboratory that will collect, test, and archive blood and DNA samples from participants in the C-Data project for use in future SCD studies. The collection of blood and DNA samples will provide researchers with an important resource to better define the genetic diversity of SCD. In the future, genotype-phenotype correlation studies, population studies, and various other genetic studies may be conducted.

This study will enroll participants taking part in the C-Data project. For this study, participants will undergo a blood collection. The blood sample will then be sent to a lab to characterize the red blood cells and hemoglobin. DNA will be analyzed to identify genes that influence the severity of SCD. Blood and DNA will be stored for future genetic research in SCD and closely related disorders. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Anemia, Sickle Cell

Clinical Trial Details

NCT number	NCT00528203
Study type	Observational
Source	National Heart, Lung, and Blood Institute (NHLBI)
Contact
Status	Terminated
Phase	N/A
Start date	August 2007
Completion date	September 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06078696` - Siplizumab for Sickle Cell Disease Transplant	Phase 1/Phase 2
Completed	`NCT04134299` - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease	N/A
Completed	`NCT02561312` - Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Completed	`NCT00890396` - Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Completed	`NCT00059293` - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Terminated	`NCT00034528` - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia	Phase 2
Completed	`NCT00005277` - Cooperative Study of The Clinical Course of Sickle Cell Disease	N/A
Active, not recruiting	`NCT04170348` - Daily Vitamin D for Sickle-cell Respiratory Complications	Phase 2
Completed	`NCT04584528` - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease	N/A
Recruiting	`NCT02286154` - Therapeutic Response Evaluation and Adherence Trial (TREAT)	N/A
Completed	`NCT02857023` - Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease	N/A
Withdrawn	`NCT01925001` - Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis	Phase 2
Terminated	`NCT00122980` - Stroke With Transfusions Changing to Hydroxyurea	Phase 3
Completed	`NCT00246077` - Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport	N/A
Completed	`NCT00094887` - Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises	Phase 2
Completed	`NCT00035763` - Pain in Sickle Cell Epidemiologic Study	N/A
Terminated	`NCT04091737` - CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease	Phase 1
Completed	`NCT00005300` - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease	N/A
Recruiting	`NCT04351698` - SMILES: Study of Montelukast in Sickle Cell Disease	Phase 2/Phase 3
Not yet recruiting	`NCT06290401` - A Socio-ecological Approach for Improving Self-management in Adolescents With SCD	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Establishing a Repository of Blood and DNA Samples From People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Genotype-Phenotype Database and Sample Repository) — Gen/Phen

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms